Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
about
A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancerTrial watch - inhibiting PARP enzymes for anticancer therapyMiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerThe fate of chemoresistance in triple negative breast cancer (TNBC)PARPs and the DNA damage responseUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicDual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activityNovel genes associated with lymph node metastasis in triple negative breast cancerSam68 Is Required for DNA Damage Responses via Regulating Poly(ADP-ribosyl)ationTriple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.A colorimetric and smartphone readable method for uracil-DNA glycosylase detection based on the target-triggered formation of G-quadruplex.Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez)Saccharomyces cerevisiae as a model system to study the response to anticancer agents.TGFβ induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genesStem cell-like gene expression in ovarian cancer predicts type II subtype and prognosisDifferential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cellsIdentification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.Biological and clinical significance of PARP1 protein expression in breast cancer.CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.Poly(ADP-ribosyl) glycohydrolase prevents the accumulation of unusual replication structures during unperturbed S phaseManagement options in triple-negative breast cancerRadiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.Genetic variation in cell cycle regulatory gene AURKA and association with intrinsic breast cancer subtype.A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.Templated chemistry for monitoring damage and repair directly in duplex DNAIdentification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.Expanding targets of DNAzyme-based sensors through deactivation and activation of DNAzymes by single uracil removal: sensitive fluorescent assay of uracil-DNA glycosylaseDirect fluorescence monitoring of DNA base excision repair8-Amino-adenosine activates p53-independent cell death of metastatic breast cancersPredicting enhanced cell killing through PARP inhibition.Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome.mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.Monitoring eukaryotic and bacterial UDG repair activity with DNA-multifluorophore sensorsTargeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.
P2860
Q24632225-49D3FDFF-408C-461E-86F1-16498E453205Q26745673-E40D4452-A077-4D85-B487-E7497358662BQ26775086-7DB02F69-4774-4D36-BDD1-2A7D86396222Q26775232-9577EBCA-2D65-4768-A67A-9D35EAE334DBQ26859010-60EA3B00-BED7-4C11-BF41-21C18BD2F087Q28071541-A69C691E-F72A-4654-909B-25571B563B40Q28304985-5C885CD3-EB2A-4DA8-B896-472DFF8B46EEQ28393204-F62C9F15-2EAA-44DA-AC2A-3E42A8A5980FQ28554210-92C22875-C055-4A1D-BFC8-CAC8FA157763Q31102636-15206556-47B1-43FA-97B1-954D116BAE8DQ33442902-CD65B79D-B3E1-47FD-AC37-45972ABA3F9CQ33851843-761303A5-DEBD-4A19-AF58-F64055B9A614Q34075999-F7FBA511-F890-497F-A9AE-FFF48D9568C0Q34291657-631B6903-2A27-452A-9125-36AF997BC2E6Q34518332-D18CE934-5EE8-4923-8936-AB1EE0E013BEQ34639023-7F7EB804-81BB-45AD-AB80-D655E2B48CE4Q34978267-4FB0CB02-3C61-4C1D-9233-41FC59AFE6D1Q35000673-905350D8-9CE3-4571-9DD0-AEA0F3817401Q35018746-448081AF-F007-4B3E-8AC3-CC22C5AB6386Q35020363-52B0A35E-786A-4C0A-A62E-E1AE20C3DCA7Q35064727-1FB158E0-26AC-4FF8-A457-9D98968EC81FQ35069579-43F73C68-22BA-42DC-8838-D9869FEDB250Q35155460-4D49630F-C1AD-4CD1-A8FD-D387EB47CD53Q35163874-1AB9F062-D8D4-4725-9398-485B8EF72D60Q35191464-B55B0A31-D8DF-46BA-9C43-AEB1B23909D9Q35450400-326CC82F-2A7E-4ACB-8EDE-E154357F2B10Q35470003-BCEC89D3-B3C5-4D0C-85B3-5BC687D23A2AQ35627868-806D37D9-D9A3-4DCE-8FEB-35E81FB5B29BQ36095938-87DFBA55-96D1-4602-AAF0-CB4F1A31767CQ36158008-31983D02-615A-46F1-8014-14C434F8DE9BQ36166929-EC736B01-D2E9-4617-9884-6157529907B9Q36439002-B0ED76EA-FDEB-40BA-A79C-A60A38D3A999Q36482186-324CAD5A-457E-4D8D-B422-EB5EE21A6248Q36503015-1725010B-F264-4275-9AD1-3A5599A4A856Q36553266-2A9298A4-2ACC-4060-B553-7B977AC13F1EQ36720582-E1F1FA67-26DF-4E56-8D93-88DF6811E2CEQ36874139-251D6F04-51EB-4604-820E-D078DF0F7295Q36963330-A6599E80-1C54-4500-9D25-B016B72DE414Q37166313-306CFE05-E70C-453E-BD47-CA86CE73F9C7Q37244880-82559193-56A4-4A68-861A-C35BD2B9E135
P2860
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Poly(ADP-Ribose) polymerase in ...... triple-negative breast cancer.
@ast
Poly(ADP-Ribose) polymerase in ...... triple-negative breast cancer.
@en
type
label
Poly(ADP-Ribose) polymerase in ...... triple-negative breast cancer.
@ast
Poly(ADP-Ribose) polymerase in ...... triple-negative breast cancer.
@en
prefLabel
Poly(ADP-Ribose) polymerase in ...... triple-negative breast cancer.
@ast
Poly(ADP-Ribose) polymerase in ...... triple-negative breast cancer.
@en
P2093
P2860
P1476
Poly(ADP-Ribose) polymerase in ...... triple-negative breast cancer.
@en
P2093
Carey K Anders
Daniel P Silver
Eric P Winer
George W Sledge
Lisa A Carey
Rebecca Dent
P2860
P304
P356
10.1158/1078-0432.CCR-10-0939
P407
P50
P577
2010-09-21T00:00:00Z